Loading…
Korean biotech developing udenafil, a PDE5-inhibitor drug studied for single-ventricle heart disease in Fontan-procedure patients.
Korean biotech developing udenafil, a PDE5-inhibitor drug studied for single-ventricle heart disease in Fontan-procedure patients.
Has no approved product of its own, so it relies on raising money from investors while its trials proceed. Udenafil already sells in some countries for erectile dysfunction, which lets it draw on an existing safety record for the heart indication.
Moat: narrow (IP / patents). Patented use of udenafil in a rare pediatric heart condition, backed by US clinical trial data.
Headquarters: Seoul, South Korea · Employees: 18
Size Mezzion Pharma (140410.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.42B, the 179th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩62,600 on 6 Nov 2026.
Performance Over six months the shares fell 28.6%, against -16.6% for the median peer and -24.5% for the South Korea market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 6.9% over the last twelve months (peer median +14.9%); the operating margin is -223.1% (peer median 10.9%).
Valuation It trades at 226.6× enterprise value to sales against a peer median of 5.2× (most expensive of 18).
Capital Return on invested capital runs 93.4 points below its cost of capital (7.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩8.43B | ₩7.91B | ₩8.61B | ₩31.7B | ₩30.7B |
| Revenue growth | — | -8% | -73% | +3% | — |
| Gross profit | ₩630M | ₩464M | ₩953M | ₩2.59B | -₩1.60B |
| EBITDA | -₩17.9B | -₩15.8B | -₩13.3B | -₩12.9B | -₩21.7B |
| Net income | -₩27.4B | -₩34.9B | -₩19.5B | -₩12.7B | -₩36.3B |
| Free cash flow | -₩20.6B | -₩16.7B | -₩19.1B | -₩11.6B | -₩12.8B |
| Capital expenditure | ₩11.2B | ₩13.3B | ₩13.5B | ₩11.9B | ₩1.76B |
| Total debt | ₩17.3B | ₩11.9B | ₩1.62B | ₩2.24B | ₩3.71B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 140410.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -6.5% | 10th lowest of 21 |
| 6-month return | -28.6% | -16.6% | 9th lowest of 21 |
| Distance from 52-week high | -65.2% | -40.1% | 3rd lowest of 21 |
| Revenue growth (TTM) | +6.9% | +14.9% | 6th lowest of 18 |
| Operating margin | -223.1% | 10.9% | 3rd lowest of 18 |
| EV / Sales | 226.6× | 5.2× | most expensive of 18 |
| ROIC minus cost of capital | -93.4 pp | -4.7 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | 15.5× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |